What To Do With $3.4 Billion? Deals And Dividends Says BMS’ Andreotti
This article was originally published in The Pink Sheet Daily
BMS plans to use the $3.4 billion it will receive shortly from AstraZeneca for selling its stake in their diabetes JV to fund a dividend increase, business development and possibly a share repurchasing program, Andreotti tells investors at the Goldman Sachs meeting.
You may also be interested in...
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.
In acquiring Amylin at a hefty premium, Bristol-Myers Squibb and its partner AstraZeneca are highly optimistic about prospects for Amylin’s GLP-1 franchise, and also hope to leverage their existing infrastructure as their fledgling diabetes franchise struggles to meet expectations.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?